FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379284480> ?p ?o ?g. }

• W4379284480 endingPage "505" @default.
• W4379284480 startingPage "505" @default.
• W4379284480 abstract "505 Background: Increased TILs are associated with better prognosis in triple-negative BC, including in patients (pts) age < 40. However, the role of TILs remains unclear in HR+/HER2- BC and little data exist in young pts, in whom immune microenvironment could be altered by age-related host/tumor differences. We assessed the extent and composition of immune infiltration in HR+ tumors of young women and correlated with clinicopathologic features and survival outcomes. Methods: From a prospective cohort study of women with BC diagnosed age ≤40, we identified those with stage I-III HR+/HER2- BC and available pre-treatment (tx) tumor tissue. Multiplexed immunofluorescence was used to quantify cytotoxic T (CD8+), T helper (Th, CD3+CD8-), T regulatory (Tregs, FOXP3+CD3+) and exhausted T (PD1+CD8+) cells in stroma and tumor. Univariate analyses tested associations between clinicopathologic variables and immune markers by high or low expression, divided based on median. High vs. low TILs were evaluated in Cox regression analyses for invasive breast cancer-free survival (iBCFS), distant disease-free survival (DDFS) and overall survival (OS). Results: In 390 pts, median age was 37 years (21-40), most had grade 2 (51%), T1 (65%), N0 (63%) tumors and 67% received adjuvant chemotherapy. Black pts (n = 17) had higher expression of stromal CD8+ ( P= .010), FOXP3+CD3+ ( P= .027) and PD1+CD8+ TILs ( P= .043); intratumoral TILs did not differ by race. Older age (36-40) was associated with high expression of CD8+ ( P= .033) and PD1+CD8+ TILs ( P= .031) within stroma and CD3+CD8- TILs within tumor ( P= .046). Grade 3 tumors had higher stromal and intratumoral expression of CD3+CD8- ( P= .002; P< .001) and FOXP3+CD3+ TILs ( P= .020; P< .001). No differences in TILs were seen according to recency of pregnancy, BRCA1/2 status or T/N stage. Over a median follow up of 8 years, 85 iBCFS events, 64 DDFS events and 37 deaths occurred. High stromal expression of CD3+CD8- TILs was associated with better iBCFS (HR 0.49, P= .002) and DDFS (HR 0.57, P= .046), which remained significant when adjusted for T/N stage, grade and chemotherapy (iBCFS HR 0.41, P< .001; DDFS HR 0.45, P= .008). High stromal expression of CD3+CD8- and FOXP3+CD3+ TILs was associated with better OS (HR 0.47, P= .038) and iBCFS (HR 0.58, P= .018), respectively, on adjusted analyses only. High intratumoral expression of CD3+CD8- and FOXP3+CD3+ TILs was associated with better iBCFS (HR 0.59, P= .025; HR 0.63, P= .043) after adjustment only. Conclusions: The distribution of TIL subtypes in young women’s HR+ BC varied according to race, age and grade. High stromal and intratumoral expression of Th and Tregs was associated with improved BC outcomes. Characterization of immune cell subsets could help refine the prognostic value of TILs in HR+ BC, particularly in young pts who may benefit from individualized escalated/de-escalated tx strategies." @default.
• W4379284480 created "2023-06-05" @default.
• W4379284480 creator A5001562050 @default.
• W4379284480 creator A5010429902 @default.
• W4379284480 creator A5018198342 @default.
• W4379284480 creator A5024343477 @default.
• W4379284480 creator A5024392666 @default.
• W4379284480 creator A5024543136 @default.
• W4379284480 creator A5027044033 @default.
• W4379284480 creator A5029062544 @default.
• W4379284480 creator A5034830236 @default.
• W4379284480 creator A5039694693 @default.
• W4379284480 creator A5049212930 @default.
• W4379284480 creator A5060188343 @default.
• W4379284480 creator A5062515397 @default.
• W4379284480 creator A5067129820 @default.
• W4379284480 creator A5085702480 @default.
• W4379284480 creator A5025041221 @default.
• W4379284480 date "2023-06-01" @default.
• W4379284480 modified "2023-10-02" @default.
• W4379284480 title "Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2- breast cancer (BC)." @default.
• W4379284480 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.505" @default.
• W4379284480 hasPublicationYear "2023" @default.
• W4379284480 type Work @default.
• W4379284480 citedByCount "0" @default.
• W4379284480 crossrefType "journal-article" @default.
• W4379284480 hasAuthorship W4379284480A5001562050 @default.
• W4379284480 hasAuthorship W4379284480A5010429902 @default.
• W4379284480 hasAuthorship W4379284480A5018198342 @default.
• W4379284480 hasAuthorship W4379284480A5024343477 @default.
• W4379284480 hasAuthorship W4379284480A5024392666 @default.
• W4379284480 hasAuthorship W4379284480A5024543136 @default.
• W4379284480 hasAuthorship W4379284480A5025041221 @default.
• W4379284480 hasAuthorship W4379284480A5027044033 @default.
• W4379284480 hasAuthorship W4379284480A5029062544 @default.
• W4379284480 hasAuthorship W4379284480A5034830236 @default.
• W4379284480 hasAuthorship W4379284480A5039694693 @default.
• W4379284480 hasAuthorship W4379284480A5049212930 @default.
• W4379284480 hasAuthorship W4379284480A5060188343 @default.
• W4379284480 hasAuthorship W4379284480A5062515397 @default.
• W4379284480 hasAuthorship W4379284480A5067129820 @default.
• W4379284480 hasAuthorship W4379284480A5085702480 @default.
• W4379284480 hasConcept C114684123 @default.
• W4379284480 hasConcept C121608353 @default.
• W4379284480 hasConcept C126322002 @default.
• W4379284480 hasConcept C143998085 @default.
• W4379284480 hasConcept C144301174 @default.
• W4379284480 hasConcept C167672396 @default.
• W4379284480 hasConcept C203014093 @default.
• W4379284480 hasConcept C2776107976 @default.
• W4379284480 hasConcept C2778326572 @default.
• W4379284480 hasConcept C2779727006 @default.
• W4379284480 hasConcept C38180746 @default.
• W4379284480 hasConcept C530470458 @default.
• W4379284480 hasConcept C71924100 @default.
• W4379284480 hasConcept C8891405 @default.
• W4379284480 hasConceptScore W4379284480C114684123 @default.
• W4379284480 hasConceptScore W4379284480C121608353 @default.
• W4379284480 hasConceptScore W4379284480C126322002 @default.
• W4379284480 hasConceptScore W4379284480C143998085 @default.
• W4379284480 hasConceptScore W4379284480C144301174 @default.
• W4379284480 hasConceptScore W4379284480C167672396 @default.
• W4379284480 hasConceptScore W4379284480C203014093 @default.
• W4379284480 hasConceptScore W4379284480C2776107976 @default.
• W4379284480 hasConceptScore W4379284480C2778326572 @default.
• W4379284480 hasConceptScore W4379284480C2779727006 @default.
• W4379284480 hasConceptScore W4379284480C38180746 @default.
• W4379284480 hasConceptScore W4379284480C530470458 @default.
• W4379284480 hasConceptScore W4379284480C71924100 @default.
• W4379284480 hasConceptScore W4379284480C8891405 @default.
• W4379284480 hasIssue "16_suppl" @default.
• W4379284480 hasLocation W43792844801 @default.
• W4379284480 hasOpenAccess W4379284480 @default.
• W4379284480 hasPrimaryLocation W43792844801 @default.
• W4379284480 hasRelatedWork W2080780959 @default.
• W4379284480 hasRelatedWork W2580010955 @default.
• W4379284480 hasRelatedWork W2599346721 @default.
• W4379284480 hasRelatedWork W3038679504 @default.
• W4379284480 hasRelatedWork W3099981825 @default.
• W4379284480 hasRelatedWork W3179174770 @default.
• W4379284480 hasRelatedWork W3194381224 @default.
• W4379284480 hasRelatedWork W3208200361 @default.
• W4379284480 hasRelatedWork W3208891510 @default.
• W4379284480 hasRelatedWork W4291378227 @default.
• W4379284480 hasVolume "41" @default.
• W4379284480 isParatext "false" @default.
• W4379284480 isRetracted "false" @default.
• W4379284480 workType "article" @default.